Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Cellectis S.A. - American Depositary Shares
(NQ:
CLLS
)
1.572
+0.002 (+0.15%)
Streaming Delayed Price
Updated: 10:46 AM EST, Dec 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
6,098
Open
1.570
Bid (Size)
1.550 (14)
Ask (Size)
1.600 (1)
Prev. Close
1.570
Today's Range
1.530 - 1.610
52wk Range
1.530 - 3.550
Shares Outstanding
45,484,310
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
December 10, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
November 05, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Performance
YTD
-48.78%
-48.78%
1 Month
-19.78%
-19.78%
3 Month
-28.53%
-28.53%
6 Month
-17.68%
-17.68%
1 Year
-54.95%
-54.95%
More News
Read More
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
November 04, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
October 30, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
October 22, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
September 03, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
August 26, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
August 07, 2024
From
Cellectis Inc.
Via
GlobeNewswire
CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
Via
InvestorPlace
Cellectis Provides Financial Results for the Second Quarter 2024
August 06, 2024
From
Cellectis Inc.
Via
GlobeNewswire
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
August 01, 2024
From
Cellectis Inc.
Via
GlobeNewswire
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
July 25, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
June 28, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
June 20, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
June 12, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
June 04, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024
May 29, 2024
From
Cellectis Inc.
Via
GlobeNewswire
CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024
May 28, 2024
Via
InvestorPlace
Cellectis Reports Financial Results for First Quarter 2024
May 28, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
May 27, 2024
From
Cellectis Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 07, 2024
Via
Benzinga
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
May 06, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
May 02, 2024
From
Cellectis Inc.
Via
GlobeNewswire
CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023
April 29, 2024
Via
InvestorPlace
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
April 29, 2024
From
Cellectis Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.